Piper Sandler Reiterates Overweight on Teva Pharma (TEVA) as Management Provides Updates
Tweet Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $23.00 price target on Teva Pharma (NYSE: TEVA).The analyst said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
